可溶性尿激酶型纤溶酶原激活物受体在ICU感染患者病情严重程度及预后评价中的研究进展

Research Progress of Soluble Urokinase Plasminogen Activator Receptor in Disease Severity and Prognosis Evaluation of ICU Infected Patients

感染是引起重症监测治疗病房(ICU)患者死亡和不良预后的主要原因,对感染性疾病进行早期诊断、判断疾病严重程度、评估患者预后并指导有效地治疗可显著减少不良预后和病死率。可溶性尿激酶型纤溶酶原激活物受体(suPAR)是一种新型的炎性反应标志物,在各种感染性疾病中其表达水平会升高,具有较高的诊断价值;可作为一种独立风险因子,预测ICU重症患者的不良预后;同时也是ICU患者疾病严重程度的标志。

Infection is a main cause of mortality and poor prognosis in ICU patients.Early diagnosis for infectious disease,judging the severity of disease,evaluating prognosis of patients and guiding effective treatment can reduce mortality and poor prognosis effectively.Soluble urokinase plasminogen activator receptor （suPAR） is a new type of inflammation markers.The expression levels of suPAR tend to rise in a variety of infectious diseases and suPAR has a high diagnostic value.It can be used as an independent risk factor in order to predict poor prognosis of critical patients in ICU,and it is also the sign of disease severity of ICU patients.